Statement: in the primary clinical trial, the proportion of patients experiencing severe side effects that block the increase in treatment dose or intensity is reported for those undergoing a combined treatment of neratinib and paclitaxel.
Primary_evidence: Outcome Measurement:    Dose Limiting Toxicity Incidence of Neratinib in Combination With Paclitaxel   Dose Limiting Toxicity in subjects with solid tumors treated with neratinib, administered daily, in combination with paclitaxel 80 mg/m² IV on days 1, 8, and 15 of a 28 day cycle.   Time frame: From first dose date through day 28 Results 1:    Arm/Group Title: Neratinib 160 mg + Paclitaxel 80 mg/m    Arm/Group Description: Neratinib 160 mg qd + Paclitaxel 80 mg/m  IV on days 1, 8, and 15 of a 28 day cycle.   Overall Number of Participants Analyzed: 3   Measure Type: Count of Participants   Unit of Measure: Participants  0   0.0% Results 2:    Arm/Group Title: Neratinib 240 mg + Paclitaxel 80 mg/m    Arm/Group Description: Neratinib 240 mg qd + Paclitaxel 80 mg/m  IV on days 1, 8, and 15 of a 28 day cycle.   Overall Number of Participants Analyzed: 5   Measure Type: Count of Participants   Unit of Measure: Participants  0   0.0%